Drug Trial Radar · NCT06814496
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 8, 2025
Primary completion
May 2030
Study completion May 2030
Sponsor
- Lead sponsor
- University of ArizonaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amgen
- First posted
- Feb 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. III) If sequential tarlatamab and radiation is not deemed safe, we would allow for continued enrollment to assess efficacy of drug sans radiation treatment, enriching for tumors not of small cell lung cancer histology and allowing for patients without sites amenable to RT. A nested phase II study will attempt to assess for ORR and safety of study intervention amongst tumors not of small cell lung cancer histology.
Conditions
- Melanoma
- Medullary Thyroid Cancer
- Sinonasal Undifferentiated Carcinoma
- Esthesioneuroblastoma
- Bladder Cancer
- Testicular Cancer
- Glioblastoma Multiforme
- Cervical Cancer
- Large Cell Neuroendocrine Carcinoma of the Lung
- Non Small Cell Lung Cancer
- Merkel Cell Carcinoma
Interventions
TarlatamabDrug
Tarlatamab will be administered at a step-up dose of 1mg on Cycle 1 Day 1 and then 10 mg on Cycle 1 Day 8 and Cycle 1 Day 15 and every 2 weeks thereafter. For cycle 2 onwards, tarlatamab infusion will occur every 2 weeks on days 1 and 15 of each cycle.
Concurrent Radiation TherapyRadiation
Standard of care RT can begin as early as Cycle 1 Day 16 and as late as Cycle 2 Day 28, assuming there is no ongoing CRS (extracranial)/ICANS (cranial).
Sequential Radiation therapyRadiation
Standard of care radiation therapy can occur prior to Cycle 1 Day 1 (if radiation treatment is completed \<7 days prior to the start of tarlatamab) or be interdigitated with tarlatamab with a 7-day washout between RT and infusion, with RT to begin as early as Cycle 1 Day 22 and as late as cycle 2 Day 28, assuming no ongoing CRS (extracranial)/ICANS (cranial).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants experiencing dose limiting toxicities (DLT) attributed to radiation or combination of radiation and tarlatamab.Time frame: Until radiographic or disease progression or up to 24 months, whichever is earlier.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Arizona Cancer Center at UMC North/University Medical Center
Tucson, Arizona · Recruiting
University of Washington Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.